

STATE OF FLORIDA
BOARD OF PHARMACY

FILED
DEPARTMENT OF HEALTH
DEPUTY CLERK
CLERK: *Rachelle*
DATE 9-14-07

In Re: PETITION OF **BILL SAELINGER, R. PH.**
FOR APPROVAL OF CONTINUING EDUCATION
CREDIT FOR COLLEGE LEVEL COURSEWORK

ORDER GRANTING PETITION

THIS MATTER came before the Board of Pharmacy (hereinafter "the Board"), at a duly noticed public meeting held on August 15, 2007, in Orlando, Florida, on the petition of Bill Saelinger (hereinafter "Petitioner"), for approval of continuing education credit for college level coursework. (A copy of the Petition is attached hereto and incorporated as Exhibit A)

The Petitioner was not present or represented. The Board was represented by Reginald D. Dixon, Assistant Attorney General.

After a complete review of the record in this matter, including consideration of the Petition, the Board approved the submitted coursework for 30 hours of general continuing education hours, excluding the specific subject area of "Medication Errors". Therefore it is

ORDERED AND ADJUDGED that:

The Petition is granted and the college level coursework is approved for 30 hours of general continuing education, excluding "Medication Errors."

This Order shall become effective upon filing with the clerk of the Department of Health.

DONE AND ORDERED, this 13 day of September, 2007.

BOARD OF PHARMACY



Rebecca R. Poston, R. Ph.
Executive Director
Florida Board of Pharmacy

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that a true and correct copy of the foregoing has been furnished by U.S. Mail to: **Bill Saelinger, R.Ph.**, 1320 Trailwood Drive, Neptune Beach, Florida 32266; by interoffice mail to **Reginald D. Dixon**, Assistant Attorney General, PL-01, The Capitol, Tallahassee, Florida 32399-1050 this 14th day of September, 2007.


Deputy Agency Clerk

F:\Users\ADMIN\Reginald Dixon\Pharmacy\Orders\Aug 07\Order.GR.Pet.CEU.Saelinger.rtf



Charlie Crist
Governor

Ana M. Viamonte Ros, M.D., M.P.H.
State Surgeon General

DATE: July 5, 2007
TO: Board of Pharmacy Members
THRU: Rebecca R. Poston, R.Ph., C.Ph.
Executive Director
THRU: Daisy King ^{D.K.}
Regulatory Supervisor
FROM: Elizabeth Ranne
Regulatory Specialist II
Re: Continuing Education Course Approval

Mr. Bill Saelinger, PS 24151 is requesting review and approval of continuing education credit for college courses completed during the biennium 10/1/2005-09/30/2007.

6/14/07

Florida State Board of Pharmacy
Rebecca Poston
4052 Bald Cypress Way
Tallahassee, Fl 32399

Board of
JUN 25 2007
Pharmacy

Dear Rebecca,

I am a 3rd year pharmacy student in the WPPD program at UF in Gainesville, Fl. My anticipated graduation date is Dec 2007. This letter pertains to my re-licensure due in September 2007. Enclosed are descriptions of each semester throughout the 3 year program. I am asking for approval of the continuing education CEU's to be applied toward this renewal. Please respond to billsael@comcast.net or forward to my home address at 1320 Trailwood Dr. Neptune Beach, Fl. 32266. My cell # 904-955-8213
Thank you.

Sincerely,

Bill Saelinger R.Ph.

Bill Saelinger R.Ph. License # PS 24151



TRANSCRIPT (UNOFFICIAL)

Board of
JUN 25 2007
Pharmacy

▼ Personal Information

Name SAELINGER WILLIAM L	UFID 16366173
Class/College 1PD	Major PD
Residency FLORIDA RESIDENT	Gender M
Birthdate 05/14/1952	

Grade/Hour Totals

Hours Earned	Hours Carried	Grade Points	GPA	Transfer Hours
42.00	42.00	141.00	3.35	

*** SPRING 2004 * CLASS = 1 COLLEGE = PD
ADMITTED TO PHARMACY DOCTORAL PROGRAM

COURSE	SECT	GRADE	CREDIT	CREDIT EARNED	CREDIT FOR GPA	COURSE TITLE
PHA 5629	8601	A	6.0	6.0	6.0	FOUNDAT PHARM CARE
TERM GPA = 4.00 * EARNED 6.00 HRS * EARNED 24.00 GPTS * CARRIED 6.00 HRS						

* SUMMER C 2005 * CLASS = 1 COLLEGE = PD

COURSE	SECT	GRADE	CREDIT	CREDIT EARNED	CREDIT FOR GPA	COURSE TITLE
PHA 5595	9281	C+	6.0	6.0	6.0	CARE/PATIENT RESPIRA
TERM GPA = 2.50 * EARNED 6.00 HRS * EARNED 15.00 GPTS * CARRIED 6.00 HRS						

***** FALL 2005 * CLASS = 1 COLLEGE = PD

COURSE	SECT	GRADE	CREDIT	CREDIT EARNED	CREDIT FOR GPA	COURSE TITLE
PHA 5596	5133	B+	6.0	6.0	6.0	CARE/PATIENT DIGESTIV
TERM GPA = 3.50 * EARNED 6.00 HRS * EARNED 21.00 GPTS * CARRIED 6.00 HRS						

*** SPRING 2006 * CLASS = 1 COLLEGE = PD

COURSE	SECT	GRADE	CREDIT	CREDIT EARNED	CREDIT FOR GPA	COURSE TITLE
PHA 5598	4724	B	6.0	6.0	6.0	CARE/PATIENT PSYCHIA
TERM GPA = 3.00 * EARNED 6.00 HRS * EARNED 18.00 GPTS * CARRIED 6.00 HRS						

* SUMMER C 2006 * CLASS = 1 COLLEGE = PD

COURSE	SECT	GRADE	CREDIT	CREDIT EARNED	CREDIT FOR GPA	COURSE TITLE
PHA 5597	7341	B+	6.0	6.0	6.0	CARE/PAT PROTECT DIS
TERM GPA = 3.50 * EARNED 6.00 HRS * EARNED 21.00 GPTS * CARRIED 6.00 HRS						

***** FALL 2006 * CLASS = 1 COLLEGE = PD

COURSE	SECT	GRADE	CREDIT	CREDIT EARNED	CREDIT FOR GPA	COURSE TITLE
PHA 5591	8010	B+	6.0	6.0	6.0	CARE/PATIENT CIRCULA
TERM GPA = 3.50 * EARNED 6.00 HRS * EARNED 21.00 GPTS * CARRIED 6.00 HRS						

*** SPRING 2007 * CLASS = 1 COLLEGE = PD

COURSE	SECT	GRADE	CREDIT	CREDIT EARNED	CREDIT FOR GPA	COURSE TITLE
PHA 5592	3966	B+	6.0	6.0	6.0	CARE/PATIENT CARDIAC
TERM GPA = 3.50 * EARNED 6.00 HRS * EARNED 21.00 GPTS * CARRIED 6.00 HRS						

Board of
JUN 25 2007
Pharmacy

Quick Scan
 WPPD Spring 2008 Course - PHA 5598

10/21

Unit A			Unit B			Unit C		
DVD	TOPIC	SPEAKER	DVD	TOPIC	SPEAKER	DVD	TOPIC	SPEAKER
Module 1	Course Introduction	Nowmos	Module 1	Pain Management Overview	Clark-Vetri	Module 1	Psychiatric Patient Evaluation	Kehoe
Module 2	Epilepsy	Ryan	Module 2	Pain Management Use of Analgesics	Clark-Vetri	Module 2	Child and Adolescent Psychiatric Conditions	Kehoe
Module 3	Status Epilepticus	Ryan	Module 3	Sleep Disorders	Baeta	Module 3	Schizophrenia	Kehoe
Module 4	Multiple Sclerosis	Ryan	Module 4	Geriatrics	Baeta	Module 4	Depressive Disorders	Kehoe
Module 5	Headache	Ryan	Module 5	Alzheimer's Disease	Binaso	Module 5	Substance Abuse	Kehoe
Module 6	Traumatic Brain Injury	Bandali	Module 6	Parkinson's Disease	Ryan	Module 6	Bipolar Disorder	Stwalley
Module 7	Central Nervous System Infections	Bandali	Module 7	Rheumatoid Arthritis Removed		Module 7	Anxiety Disorders	Stwalley
						Module 8	Eating Disorders	Kehoe
Experiential Sessions								
Session 1 - January 28			Session 2 - February 25			Session 3 - March 25		
<ul style="list-style-type: none"> - Orientation - Homework - Schwinghammer - PC Writing Papers Status Presentations - Individual Case Presentations - 1/2 class - Substance Abuse Presentation - 1/2 class - Neurological System Workshop - Longitudinal Case Report 			<ul style="list-style-type: none"> - Exam #1 (2 hours) - Homework - Schwinghammer / Kinetic problems - Individual Case Presentations - 1/2 class - Game - Completed CPA's turned in 			<ul style="list-style-type: none"> - Exam #2 (1 hour) - Homework - Schwinghammer - Longitudinal Patient Case Presentation - Substance Abuse Presentation - 1/2 class - Ethical Dilemmas 		

1301

Session A Session B Session C								
TOPIC	SPEAKER	TAPE	TOPIC	SPEAKER	TAPE	TOPIC	SPEAKER	
A1 0.5 hr	Orientation	Feild	B1 1 hr	AIDS/HIV	Orrick	C1 0.75 hr	Peds immunizations	Williams
A2 1.5 hrs	Function and Evaluation of the Immune system	Mitzryk	B2 1 hr	HIV treatment /resistance	Orrick	C2 0.75 hr	Adult immunizations	Mitzryk
A3 0.75 hr	Acne	Cheigh	B3 1.5 hr	HIV opportunistic and HIV TB	Orrick	C3 1 hr	Immunization demonstration and practice update interview	Ohri
A4 0.75 hr	Psoriasis	Cheigh	B4 0.5 hr	Febrile Neutropenia	Fancher	C4 1 hr	SLE	Weizer
A5 1.25 hr	A practical approach to common dermatologic ailments	Cheigh	B5 1 hr	Systemic fungal infections	Sivik	C5 1 hr	Osteoarthritis	Covey
A6 0.5 hr	Sun Burns / Sun Screens / Skin Cancer	Covey	B6 1 hr	Systemic Inflammatory Response Syndrome /Sepsis	Feild	C6 1 hr	Osteomyelitis	Mitzryk
A7 0.5 hr	Allergic Drug Reactions	Doering	C7 0.5 hr	Gout	Wear			
A8 1 hr	Stem Cell Transplant	Fancher	C8 1hr	Rheumatoid arthritis	Covey			
Remote Groups: Please refer to the Blackboard for the schedule of activities								
Experiential Sessions								
Session 1 – May 20th				Session 2 – June 17th		Session 3 – July 15th		

Quick Scan

WPPD Summer 2006 Course – PHA 5597

1 of 1

WPPD Fall 2005 Course – PHA 5596 Quick Scan

Unit A			Unit B			Unit C		
DVD	TOPIC	SPEAKER	DVD	TOPIC	SPEAKER	DVD	TOPIC	SPEAKER
Module 1	Course Introduction	Fitzgerald	Module 1	Inflammatory Bowel Disease: Ulcerative Colitis and Crohn's Disease	Thomson	Module 1	Assessment of Drug-drug Interactions	Lile
Module 2	GI Physiology and Drug Administration through Enteral Feeding Tubes	Grunwald	Module 2	Irritable Bowel Syndrome	Thomson	Module 2	Anticoagulation Bridging Around GI Procedures	Lile
Module 3	Drug Therapy for GERD	Vandervoort	Module 3	Alcoholic Liver Disease	Thomson	Module 3	Pancreatitis	Weizer-Simon
Module 4	H-Pylori induced Ulcers	Vandervoort	Module 4	Liver Transplantation	Rainey	Module 4	Colorectal Cancer	Clark-Vetri
Module 5	NSAID-induced Ulcers	Vandervoort	Module 5	Constipation and Diarrhea	Mattox	Module 5	Nausea and Vomiting	Clark-Vetri
Module 6	GI Hemorrhage	Troyer	Module 6	Viral Hepatitis	Simdon	Module 6	GI Infections and Enterotoxigenic Poisonings	Sun
Module 7	Drug Dosing Considerations in the Bariatric Patient	Grunwald				Module 7	Intra-abdominal Infections	Sun
Module 8	Nutrition Support: Assessment	Lopez						
Module 9	Nutrition Support: Parenteral Nutrition	Lopez						
Module 10	Enteral Nutrition	Lopez						
Experiential Sessions								
Session 1 – September 24			Session 2 – October 22			Session 3 – November 19		
<ul style="list-style-type: none"> - Orientation - Homework Review - PC Writing Papers Status Presentations - Individual Case Presentations – ½ class - Workshop – Medication Incidents – ½ class 			<ul style="list-style-type: none"> - Midterm Exam (2 hours) - Homework Review - Individual Case Presentations - ¼ class - Journal Club – ½ class - GI eparty - Completed CPA's turned in 			<ul style="list-style-type: none"> - Quiz – Drug Interactions - Homework Review - Individual Case – ¼ class - Journal Club – ½ class - Workshop – Medication Incidents – ½ class 		

1 of 1

WPPD Summer 2005 Course – PHA 5595

Quick Scan

Unit A			Unit B			Unit C		
DVD	TOPIC	SPEAKER	DVD	TOPIC	SPEAKER	DVD	TOPIC	SPEAKER
Module 1 30 min	Course Introduction	Nowmos	Module 1 35 min	Small Cell Lung Cancer	Wong	Module 1 50 min	Cystic Fibrosis	Maish
Module 2 1- 48 min 2- 38 min	Pt 1 Intro / Objective Measurement of Lung Function Pt 2 devices/counseling	Milavetz	Module 2 39 min	Non-Small Cell Lung Cancer	Wong	Module 2 50 min	Non-HIV Tuberculosis	Kam
Module 3 30 min	Allergic Rhinitis	Hendeles	Module 3 65 min	Chronic Obstructive Pulmonary Disease (Chronic)	Covey	Module 3 51 min	Otitis Media / Sinusitis	Whitby
Module 4 41 min	Pharmacotherapy of Acute Asthma	Hendeles	Module 4 58 min	Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease	Troyer	Module 4 51 min	Upper Respiratory Infections(Croup/Pertussis/RSV/ Influenza	Kelly
Module 5 45min	Pharmacotherapy of Chronic Stable Asthma	Maish	Module 5 45 min	Smoking Cessation	VanRiper	Module 5 38 min	Community Acquired Pneumonia	Kuti
Module 6 46 min	Inpatient Asthma Treatment / Status Asthmaticus	Hendeles	Module 6 52 min	Respiratory Distress Syndrome/BrochoPulmonary Displasia	Whitby	Module 6 34 min	Hospital Acquired Pncumonia	Kuti
Module 7 35 min	Drug Induced Lung Disease	Weizer-Simon	Module 7 29 min	Acute Respiratory Distress Syndrome	Grunwald			
Module 8 24 min	Primary Pulmonary Hypertension	Spurlock						
Module 9 54 min	Lung Transplant	Rainey						
Remote Groups June 24-26: Please refer to WPPD homepage (Remote) for schedule of activities.								
Experiential Sessions								
Session 1 – May 11			Session 2 – June 8			Session 3 – July 20		
<ul style="list-style-type: none"> - Orientation - Homework Review 24, 25, 100 - PC Writing Papers Status Presentations - Medication Administration / Monitoring Devices Case/workshop - Breath Sounds workshop 			<ul style="list-style-type: none"> - Midterm Exam - Homework Review 26, 27, 140 - Individual Case Presentations or PC Writing Paper Presentations (50%) - PPCP Triad Workshop - Completed CPA's turned in 			<ul style="list-style-type: none"> - Homework Review 94, 111, 112, 113, 115, 119 - Individual Case Presentations or PC Writing paper Presentations (50%) - Aminoglycoside Dosing Problems 		

P.1

(352) 846-1775

4a3d3

Jun 19 07 02:56p

Handouts

PHA 5593

A1	Orientation – Wazny
A2	Renal Anatomy & Physiology - Schwenk
A3	Fluids & Electrolytes, Parts 1, 2 and 3 - Troyer
A4	Interpreting Blood Gases (Acid-Base Disorders) - Worrall
A5	Acute Renal Failure - Weizer
B1	Drug-Induced Nephrotoxicity - Riley
B2	Preventing Progression of Chronic Kidney Disease - Wazny
B3	Drug Therapy Individualization for Patients with Renal Insufficiency - Wazny
B4	End Stage Renal Disease & Dialysis Therapies - Pai
B5	Renal Transplantation, Parts 1 and 2 – Vasquez
C1	Treatment of Urinary Tract Infections - Kam
C2	Prostatitis - Kam
C3	Benign Prostatic Hyperplasia & Management of Erectile Dysfunction - Lee
C4	Renal Cell Carcinoma – Sifontis
C5	Bladder and Prostate Carcinomas - Lenz

Course Description

This working professional course is designed to introduce the post-baccalaureate practicing pharmacist to the concepts of pharmaceutical care by requiring the student to provide services to actual patients as they learn. All the biomedical, pharmaceutical, clinical and pharmaceutical care sciences are fully integrated in the reading assignments and patient case presentations for the purpose of providing the student the opportunity to function as he/she would after graduation, but under faculty supervision. The pharmaceutical care topics emphasized during this and every semester are: gathering and processing information, patient communication and counseling, identifying and prioritizing problems, planning and effecting therapeutic interventions, and communication skills with health care providers.

This course is one in a series of eight Pharmaceutical Patient Care (PPC) courses, which are organized by organ system. This course introduces the student to PPC concepts, patient assessment, pharmacokinetics, pharmacodynamics, therapeutics, and therapeutic drug monitoring for patients with Renal Disorders.

Each student will make several presentations during the semester (see the Course Topics Schedule for additional information). In addition, there will be evaluative workshops and required on-site clinical practice assessments (see CPA guidebook for more details).

Pre-Requisites

Student must be in good academic standing with the Working Professional Doctor of Pharmacy Program having successfully completed a baccalaureate degree from an ACPE accredited college of pharmacy that included therapeutics and pharmacokinetics. For UF graduates the prerequisite course numbers are PHA 4602, 4503, 4510, and 4511 or their equivalent. The student must also be licensed and in good standing with their respective Board of Pharmacy.

Course Credits

Successful completion of this course may be used for 20 hours of general continuing education credit. Consultant Pharmacist credit (12 hours) has been applied for Consultant Pharmacists practicing in Florida. The course has also been submitted to the Florida Board and ACPE for five hours of live credit. Check with your local board to see if these hours are accepted in your state.



The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course is accredited for 20 hours (2.0 CEUs). ACPE Accreditation number will be posted on the course website. To receive credit for this course, you must receive a passing grade and complete the evaluation form. Consultant Pharmacist credit (12 hours) has been applied for Consultant Pharmacists practicing in Florida.

Course Goals

To instill in the student the ability to perform the following:

1. Investigate practice problems relating to the pharmacotherapy of patients experiencing Renal Disorders by correctly identifying data elements that must be gathered, organized, and interpreted for specific patient cases.
2. Solve these problems by identifying alternative intervention activities and choosing, implementing, and evaluating one of the options.
3. Plan, organize, direct, and manage a pharmaceutical patient monitoring system involving these patients.
4. Integrate ethical ideas and information from diverse sources, including the professional literature and other health professionals (e.g., physicians and nurses) as a means of striving to continuously improve the care of these patients.
5. Communicate, educate, and collaborate effectively in order to gather and convey ideas and information verbally and in writing, and to deal with dissenting opinions regarding these patients pharmacotherapy.
6. Participate in policy formation and professional governance of pharmacy practice at practice site to improve the clinical outcome of these patients.

Course Objectives

Upon successful completion of this course the student shall be able to demonstrate the ability to perform the following with respect to Renal Disorders:

1. Properly understand and explain anatomical, physiological, and pathophysiological conditions ameliorated by pharmacotherapy.
2. Implement rational pharmacotherapy based on a mastery of sciences:
 - a. BIOMEDICAL (anatomy, physiology, pathophysiology, infectious disease, oncology, and immunology),
 - b. PHARMACEUTICAL (medicinal chemistry, biopharmaceutics, pharmacodynamics, and pharmacokinetics),
 - c. CLINICAL (therapeutics, therapeutic drug monitoring, toxicology, nutrition, and drug information),
 - d. PHARMACEUTICAL CARE (patient interviewing techniques, chart review and data gathering, identifying interventions, establishing interventions and monitoring strategies, and communication skills with health care providers).
3. Design, implement, monitor, evaluate, document, and modify or recommend modifications in pharmacotherapy to insure effective, safe, and economical pharmaceutical care.
4. Critically evaluate new advances in biotechnology, pharmacotherapy, or systems of care and effectively utilize this new knowledge for patient care improvement.
5. Recognize, resolve, and report, if indicated, preventable drug-related problems such as inappropriate indication, therapeutic duplication, drug-disease, drug-drug interactions, incorrect drug dosage or duration of treatment, drug-allergy interactions, and clinical abuse or misuse of drugs.
6. Effectively communicate and educate patients and other healthcare professions in order to optimize pharmacotherapy and prevent future health problems.

7. Manage (plan, organize, direct, and control) personnel, resources and systems needed to deliver pharmaceutical care.
8. Properly document in writing the warnings, potential untoward effects, major precautions, and recommendations associated with a patient's drug therapy.
9. Modify drug dosage regimens based upon biopharmaceutical, clinical pharmacokinetic, pharmacodynamic, and therapeutic drug monitoring principles.
10. Recommend cost effective pharmacotherapeutic changes where therapeutic equivalency of multi-source drugs exists.
11. Apply the principles of quality assessment and quality improvement to result in better patient care outcomes.
12. Effectively present recommendations to physicians and other health care colleagues.
13. Critically evaluate scientific and professional literature to assure that appropriate statistical tests and experimental design have been used in studies relating to drug safety and efficacy.
14. Interview the patient to acquire significant information relevant to the patient's compliance with the prescribed regimen and determine if changes are needed to maximize efficacy and/or minimize any adverse effects.
15. Counsel patients regarding techniques to improve compliance, decrease the risk of adverse drug reactions, proper self-administration and self-monitoring of over-the-counter and prescription medications, proper drug storage, and actions to be taken in the event of missed doses.
16. Counsel patients regarding the epidemiology of specific illnesses and the management of specific chronic diseases.
17. Demonstrate interpersonal skills that effectively interact with patients, families, and other health professionals for the improvement in clinical outcomes.
18. Intervene in an appropriate manner when the action of a colleague may have or has resulted in unsafe or ineffective drug therapy.
19. Comply with organization, state, and federal laws governing pharmacy practice.
20. Evaluate the costs, benefits, and effectiveness of pharmacy-related services and activities.
21. Educate and train colleagues toward improving their ability to provide effective pharmaceutical care through personal interaction, presentations at in-service education programs, and participation in interdisciplinary health care, meetings, e.g. pharmacy and therapeutics committees, drug usage evaluation, infection control, and continuous quality improvement committees.

*These objectives will be rigorously followed as a blueprint for designing the lecture, home study, and practice site content and materials.

Important Reminders and Changes this Semester

1. Elimination of Schwinghammer casebook homework during the experiential sessions. "Homework" will now consist of "Applying Knowledge Workshops" that focus on specific course topics. Students are still encouraged to use the Schwinghammer casebook for additional practice on patient cases when studying for the quiz or exams. Students are required to complete these workshops prior to the session. The student's work will be checked by the facilitator prior to beginning the workshop discussion. Students who do not complete the workshop material prior to the session will receive a score of zero (unacceptable) on the Participation Evaluation Form for #3 Well-prepared and #5 Actively participates in all class workshops.
2. Slides presented 6 per page. Two per page version is posted on WebCT.
3. **CLASS ATTENDANCE IS MANDATORY AT THE EXPERIENTIAL SESSIONS AND REMOTE WEEKEND.** A form ("Request to miss part or all of a session") must now be completed by the student and approved by the student's facilitator and the course coordinator. Student will be responsible for finding a proctor for any exams missed. The form is posted on WebCT. Email completed form to facilitator and course coordinator. All three exams this semester will be 2 hours in length and each will contribute a total of 20% of your final course grade. Students must obtain at least a 70% (combined) average on the EXAMS and a 70% overall in course work in order to pass the course. You do not have to score a 70% on each exam, only the average of the three exams needs to be at least 70%.
5. Students who need to write Exam #3 (July 28, 2007 9AM-11AM) at an alternate time now must complete a form, "Request to take Exam #3 at an alternate time", and email to your facilitator & course coordinator for review. This form is posted on WebCT.

Handout *PNA 5592*

A1	Orientation – Waddell	A1-7
A2	Cardiac Anatomy, Physiology, Pathophysiology and Assessment –Troyer.....	A9-41
A3	Chronic Heart Failure, Parts 1, 2 and 3- Johnson.....	A43-59
A4	Acute Heart Failure – Shaw.....	A61-72
A5	Infectious Endocarditis – Spencer.....	A73-83
A6	Congenital Heart Defects – Whitby.....	A85-94
B1	Acute Atrial Fibrillation/Flutter – Spencer.....	B1-10
B2	Outpatient Management of Atrial Fibrillation - Covey.....	B11-19
B3	Ventricular Tachycardia/Fibrillation/Drug Induced Torsades de Pointes-Spencer...	B21-31
B4	Bradyarrhythmias – Thoms.....	B33-42
B5	ACLS: An Update – Troyer.....	B43-50
C1	Chronic Ischemia (Angina Pectoris) – Nappi.....	C1-12
C2	Acute Coronary Syndrome Part 1 – Nappi.....	C13-23
C3	Acute Coronary Syndrome Part 2 – Nappi.....	C25-34
C4	CABG and Postoperative Care – Shaw.....	C35-46
C5	Cardiac Transplant – Claridge.....	C47-58

Course Description

This working professional course is designed to introduce the post-baccalaureate practicing pharmacist to the concepts of pharmaceutical care by requiring the student to provide services to actual patients as they learn. All the biomedical, pharmaceutical, clinical and pharmaceutical care sciences are fully integrated in the reading assignments and patient case presentations for the purpose of providing the student the opportunity to function as he/she would after graduation, but under faculty supervision. The pharmaceutical care topics emphasized during this and every semester are: gathering and processing information, patient communication and counseling, identifying and prioritizing problems, planning and effecting therapeutic interventions, and communication skills with health care providers.

This course is one in a series of eight Pharmaceutical Patient Care (PPC) courses, which are organized by organ system. This course introduces the student to PPC concepts, patient assessment, pharmacokinetics, pharmacodynamics, therapeutics, and therapeutic drug monitoring for patients with cardiovascular disorders.

Each student will make several presentations during the semester (see the Course Topics Schedule for additional information). In addition, there will be evaluative workshops and required on-site clinical practice assessments (see CPA guidebook for more details).

Pre-Requisites

Student must be in good academic standing with the Working Professional Doctor of Pharmacy Program having successfully completed a baccalaureate degree from an ACPE accredited college of pharmacy that included therapeutics and pharmacokinetics. For UF graduates the prerequisite course numbers are PHA 4602, 4503, 4510, and 4511 or their equivalent. The student must also be licensed and in good standing with their respective Board of Pharmacy.

Course Credits

Successful completion of this course may be used for 20 hours of general continuing education credit. Consultant Pharmacist credit (12 hours) has been applied for Consultant Pharmacists practicing in Florida. The course has also been submitted to the Florida Board and ACPE for five hours of live credit. Check with your local board to see if these hours are accepted in your state.



The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course is accredited for 20 hours (2.0 CEUs). ACPE Accreditation number will be posted on the course website. To receive credit for this course, you must receive a passing grade and complete the evaluation form. Consultant Pharmacist credit (12 hours) has been applied for Consultant Pharmacists practicing in Florida.

Course Goals

To instill in the student the ability to perform the following:

1. Investigate practice problems relating to the pharmacotherapy of patients experiencing Cardiovascular disorders by correctly identifying data elements that must be gathered, organized, and interpreted for specific patient cases.
 2. Solve these problems by identifying alternative intervention activities and choosing, implementing, and evaluating one of the options.
 3. Plan, organize, direct, and manage a pharmaceutical patient monitoring system involving these patients.
 4. Integrate ethical ideas and information from diverse sources, including the professional literature and other health professionals (e.g., physicians and nurses) as a means of striving to continuously improve the care of these patients.
 5. Communicate, educate, and collaborate effectively in order to gather and convey ideas and information verbally and in writing, and to deal with dissenting opinions regarding these patients pharmacotherapy.
 6. Participate in policy formation and professional governance of pharmacy practice at practice site to improve the clinical outcome of these patients.
-

Course Objectives

Upon successful completion of this course the student shall be able to demonstrate the ability to perform the following with respect to cardiovascular disorders:

1. Properly understand and explain anatomical, physiological, and pathophysiological conditions ameliorated by pharmacotherapy.
2. Implement rational pharmacotherapy based on a mastery of sciences:
 - a. BIOMEDICAL (anatomy, physiology, pathophysiology, infectious disease, oncology, and immunology),
 - b. PHARMACEUTICAL (medicinal chemistry, biopharmaceutics, pharmacodynamics, and pharmacokinetics),
 - c. CLINICAL (therapeutics, therapeutic drug monitoring, toxicology, nutrition, and drug information),
 - d. PHARMACEUTICAL CARE (patient interviewing techniques, chart review and data gathering, identifying interventions, establishing interventions and monitoring strategies, and communication skills with health care providers).
3. Design, implement, monitor, evaluate, document, and modify or recommend modifications in pharmacotherapy to insure effective, safe, and economical pharmaceutical care.
4. Critically evaluate new advances in biotechnology, pharmacotherapy, or systems of care and effectively utilize this new knowledge for patient care improvement.
5. Recognize, resolve, and report, if indicated, preventable drug-related problems such as inappropriate indication, therapeutic duplication, drug-disease, drug-drug interactions, incorrect drug dosage or duration of treatment, drug-allergy interactions, and clinical abuse or misuse of drugs.
6. Effectively communicate and educate patients and other healthcare professions in order to optimize pharmacotherapy and prevent future health problems.
7. Manage (plan, organize, direct, and control) personnel, resources and systems needed to deliver pharmaceutical care.
8. Properly document in writing the warnings, potential untoward effects, major precautions, and recommendations associated with a patient's drug therapy.
9. Modify drug dosage regimens based upon biopharmaceutical, clinical pharmacokinetic, pharmacodynamic, and therapeutic drug monitoring principles.
10. Recommend cost effective pharmacotherapeutic changes where therapeutic equivalency of multi-source drugs exists.
11. Apply the principles of quality assessment and quality improvement to result in better patient care outcomes.
12. Effectively present recommendations to physicians and other health care colleagues.
13. Critically evaluate scientific and professional literature to assure that appropriate statistical tests and experimental design have been used in studies relating to drug safety and efficacy.
14. Interview the patient to acquire significant information relevant to the patient's compliance with the prescribed regimen and determine if changes are needed to maximize efficacy and/or minimize any adverse effects.
15. Counsel patients regarding techniques to improve compliance, decrease the risk of adverse drug reactions, proper self-administration and self-monitoring of over-the-counter and prescription medications, proper drug storage, and actions to be taken in the event of missed doses.
16. Counsel patients regarding the epidemiology of specific illnesses and the management of specific chronic diseases.
17. Demonstrate interpersonal skills that effectively interact with patients, families, and other health professionals for the improvement in clinical outcomes.
18. Intervene in an appropriate manner when the action of a colleague may have or has resulted in unsafe or ineffective drug therapy.
19. Comply with organization, state, and federal laws governing pharmacy practice.
20. Evaluate the costs, benefits, and effectiveness of pharmacy-related services and activities.
21. Educate and train colleagues toward improving their ability to provide effective pharmaceutical care through personal interaction, presentations at in-service education programs, and participation in interdisciplinary health care, meetings, e.g. pharmacy and therapeutics committees, drug usage evaluation, infection control, and continuous quality improvement committees.

*These objectives will be rigorously followed as a blueprint for designing the lecture, home study, and practice site content and materials.

173

© 2006 University of Florida WPPD Program PHA 5591

This Page Left Blank Intentionally

1/24

TABLE OF CONTENTS

COURSE DESCRIPTION..... 2

PRE-REQUISITES..... 3

COURSE CREDITS..... 3

COURSE GOALS..... 3

COURSE OBJECTIVES..... 4

OTHER INFORMATION..... 5

NEW THIS SEMESTER REQUIRED TEXTBOOKS..... 5

AVAILABILITY OF READINGS/LIBRARY SERVICE..... 5

OTHER REQUIREMENTS..... 6

BASIC RULES FOR DISCUSSION BOARDS..... 6

BASIC RULES FOR E-MAIL..... 6

E-MAIL..... 7

QUICK SCAN..... 8

LECTURE CONTENT / READING ASSIGNMENTS / HOMEWORK..... 10

FACULTY BIO-SKETCHES:..... 12

EXPERIENTIAL SESSIONS:..... 14

ASSIGNMENTS AND ACTIVITIES DESCRIPTION..... 15

PHARMACEUTICAL CARE (PC) WRITING PAPERS..... 17

EXAMINATION SCHEDULE..... 19

EVALUATION..... 20

GRADING SCALE..... 20

GRADING POLICY..... 20

FACULTY/COURSE/PROGRAM EVALUATION..... 22

ACADEMIC AND CONDUCT STANDARDS SUMMARY..... 22

3/8 3

pharmacodynamics, therapeutics, and therapeutic drug monitoring for patients with protective or structural system disorders.

Each student will make several presentations during the semester (see the Course Topics Schedule for additional

information). In addition, there will be evaluative workshops and required on-site clinical practice assessments (see CPA

guidebook for more details).

Pre-Requisites

Student must be in good academic standing with the Working Professional Doctor of Pharmacy Program having

successfully completed a baccalaureate degree from an ACPE accredited college of pharmacy that included therapeutics

and pharmacokinetics. For UF graduates the prerequisite course numbers are PHA 4602, 4503, 4510, and 4511 or their

equivalent. The student must also be licensed and in good standing with their respective Board of Pharmacy.

Course Credits

Successful completion of this course may be used for 20 hours of general continuing education credit.

Consultant

Pharmacist credit (12 hours) has been applied for Consultant Pharmacists practicing in Florida. The course has also

been submitted to the Florida Board and ACPE for five hours of live credit. Check with your local board to see if these

hours are accepted in your state.

The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course is accredited for 20 hours (2.0 CEUs). ACPE

Accreditation number will be posted on the course website. To receive credit for this course, you must receive a passing

grade and complete the evaluation form.

Course Goals

To instill in the student the ability to perform the following:

1. Investigate practice problems relating to the pharmacotherapy of patients experiencing Protective or structural system disorders by correctly identifying data elements that must be gathered, organized, and interpreted for specific patient cases.
2. Solve these problems by identifying alternative intervention activities and choosing, implementing, and evaluating one of the options.
3. Plan, organize, direct, and manage a pharmaceutical patient monitoring system involving these patients.
4. Integrate ethical ideas and information from diverse sources, including the professional literature and other health professionals (e.g., physicians and nurses) as a means of striving to continuously improve the care of these patients.
5. Communicate, educate, and collaborate effectively in order to gather and convey ideas and information verbally and in writing, and to deal with dissenting opinions regarding these patients pharmacotherapy.
6. Participate in policy formation and professional governance of pharmacy practice at practice site to improve the clinical outcome of these patients.

283

ACADEMIC STANDARDS

..... 22

CONDUCT

STANDARDS..... 23

Handouts

A1 Orientation - Fitzgerald.....A1-7

A2 Understanding Endothelial Function - Lopez.....A9-17

A3 Hypertension - Johnson.....A19-50

A4 Hypertension Part 2 - Johnson

A5 Hypertension Part 3 - Johnson

A6 Cholesterol and Atherosclerotic Risk Assessment - Covey.....A51-60

A7 Cholesterol Management in Special Populations - Covey.....A61-69

A8 Obesity and Weight Loss - Huynh.....A71-83

B1 Stroke/TIA - Nowmos.....B1-9

B2 Peripheral Arterial Disease - Nowmos.....B11-17

B3 Acute DVT/PE Management - Motycka.....B19-33

B4 Management of Chronic Oral Anticoagulant Therapy - Covey.....B35-47

B5 Managing Complications of Antithrombotic Therapy - Motycka.....B49-59

B6 Hypertension Pharmacogenetics - Johnson.....B61-69

B7 Warfarin Pharmacogenetics - Johnson.....B71-76

C1 Hemodynamic Monitoring - Feild.....C1-11

C2 Hypovolemic/Hemorrhagic Shock - Feild.....C13-20

C3 Distributive Shock (Sepsis) - Feild.....C21-30

C4 Managing Hypertensive Crisis - Banaldi.....C31-43

C5 Anaphylaxis and Serious Drug Reactions - Weizer.....C45-50

2/24

This Page Intentionally Blank

3/24

Course Description

This working professional course is designed to introduce the post-baccalaureate practicing pharmacist to the concepts of pharmaceutical care by requiring the student to provide services to actual patients as they learn. All the biomedical, pharmaceutical, clinical and pharmaceutical care sciences are fully integrated in the reading assignments and patient case presentations for the purpose of providing the student the opportunity to function as he/she would after graduation, but under faculty supervision. The pharmaceutical care topics emphasized during this and every semester are: gathering and processing information, patient communication and counseling, identifying and prioritizing problems, planning and effecting therapeutic interventions, and communication skills with health care providers. This course is one in a series of eight Pharmaceutical Patient Care (PPC) courses, which are organized by organ system. This course introduces the student to PPC concepts, patient assessment, pharmacokinetics,